335 EyetubeOD - NSI: The news edition - Mergers and Acquisitions in Eye Care: Shire's Positioning

49/58

previous next

NSI: The news edition - Mergers and Acquisitions in Eye Care: Shire's Positioning

by Derek Cunningham, OD, Walter Whitley, OD, MBA, FAAO

Shire has acquired Foresight Biotherapeutics to boost Shire’s position in ophthalmics. Foresight’s late-stage agent, FST-100, if approved, would be the first drug to treat both bacterial and viral eye infections. This has a clear strategic fit with lifitegrast, which is in late-stage development for treatment of dry eye disease. Derek and Walt discuss mergers and acquisitions in ophthalmics.

Comments (0)